Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on February 24, 2006. The report covers events occurring between January 11, 2006, and February 24, 2006, specifically regarding the unregistered sale of equity securities.
Key Financial Metrics
- Shares Issued: 927,157 shares of common stock issued to 15 warrant holders.
- Gross Proceeds: $1,120,450.23 received from warrant exercises.
- Commission Obligation: Approximately $31,468.01 owed to Burnham Hill Partners (a division of Pali Capital, Inc.) representing a 4% cash commission on the exercises.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions.
Material Changes
The primary material change reported is the increase in outstanding common stock due to the exercise of warrants by 15 holders. This transaction resulted in immediate cash inflow of over $1.1 million and created a specific liability for the 4% placement agent fee.
Guidance, Outlook, and Risks
- Regulatory Status: The share issuances were not registered under the Securities Act of 1933, relying instead on the exemption provided by Section 4(2).
- Contingencies: The company has an outstanding obligation to pay the $31,468.01 commission to Burnham Hill Partners.
- Outlook: The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the cash balance impact of the $1.12 million proceeds versus the $31,468 commission liability.
- Review the terms of the March 2004 agreement with Burnham Hill Partners to understand future commission obligations on remaining warrants.
- Check subsequent filings to ensure the Section 4(2) exemption was properly applied and no registration statement was subsequently required.